0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > LRRC32

LRRC32

Brief Information

Name:Transforming growth factor beta activator LRRC32
Target Synonym:Glycoprotein A Repetitions Predominant,D11S833E,Garpin,LRRC32,Leucine-Rich Repeat-Containing Protein 32,Transforming Growth Factor Beta Activator LRRC32,Leucine Rich Repeat Containing 32,GARP
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 1 Clinical

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
LR2-H5256 Human Human LRRC32 / GARP / Garpin Protein, Fc Tag
LR2-H5256-structure
LR2-H5256-sds
LR2-H5256-elisa_1

Part of Bioactivity data

LR2-H5256-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Human LRRC32, Fc Tag (Cat. No. LR2-H5256) on AHC Biosensor, can bind Human TGFB1, His Tag (Cat. No. TG1-H524x) with an affinity constant of 0.288 μM as determined in BLI assay (ForteBio Octet Red96e) (QC tested).

LR2-H5256-ELISA
Human LRRC32, Fc TagHuman LRRC32, Fc Tag (Cat. No. LR2-H5256) ELISA bioactivity

Immobilized Human LRRC32, Fc Tag (Cat. No. LR2-H5256) at 2 μg/mL (100 μL/well) can bind Cynomolgus Latent TGF-Beta 1 (C33S), His Tag (Cat. No. TG1-C5243) with a linear range of 0.039-1.25 μg/mL (Routinely tested).

Synonym Name

GARP,Garpin,D11S833E

Background

Leucine-rich repeat protein 32 (LRRC32), also known as GARP (glycoprotein A repetitions predominant). LRRC32 expression promotes the acquisition of a Treg phenotype including reduced cellular proliferation, reduced cytokine secretion, and the capacity to suppress the proliferation of naïve T cells. LRRC32 binds directly to the TGF-beta latency associated peptide (LAP) and tethers latent TGF-beta on the surface of activated Treg cells. The presentation of TGF-beta on Tregs contributes to their ability to suppress naïve T cell proliferation.

Clinical and Translational Updates

Related Molecule

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
ABBV-151 MGH-8; ABBV151; AGRX-115; ARGX-115 Phase 1 Clinical Argen-X Neoplasms Details

This web search service is supported by Google Inc.

totop